Ami Organics Limited has informed the Exchange about Transcript
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ami Organics crossed the INR 1,000 crore revenue mark in FY25, with full-year revenue of INR 1,006.9 crores, up 40.3% YoY, driven by 50% growth in Pharma Intermediates (INR 854 crores). Q4 FY25 was especially strong: revenue grew 37.1% YoY to INR 308.5 crores, EBITDA nearly doubled to INR 85 crores (margin 27.5%, up 835 bps), and PAT grew 2.5x to INR 62.7 crores. Management guided for 25% revenue growth in FY26 (a target hit for 15 straight years), margin improvement, and CDMO revenue of INR 1,000 crores by FY28. The company will rebrand to Acutaas Chemicals Limited to reflect its diversified specialty chemicals focus, sits on INR 249 crore net cash with zero debt, and plans INR 200 crore capex in FY26, including a 2,000-tonne electrolyte additives plant starting in H2 FY26.
Strong margin expansion, zero-debt balance sheet, and reaffirmed 25% growth guidance are positive signals for shareholders. New growth engines in CDMO, semiconductor, and electrolyte additives give visibility, though specialty chemicals segment growth remains weak and key product-level disclosures were limited for confidentiality.